Read by QxMD icon Read

Gastric Cancer

Xingkang He, Wenrui Wu, Zhenghua Lin, Yue Ding, Jianmin Si, Lei-Min Sun
BACKGROUND: Our aim was to validate the American Joint Committee on Cancer (AJCC) 8th edition stage system for gastric cancer in the Western world and to compare several modifications between the 7th and 8th edition systems. METHODS: Eligible patients having undergone surgical resection of gastric cancer during 2004-2011 from the Surveillance, Epidemiology, and End Results (SEER) database were included in the current study. Survival differences were assessed by Kaplan-Meier curve and log-rank tests...
October 20, 2017: Gastric Cancer
Sunpyo Lee, Kee Don Choi, Minkyu Han, Hee Kyong Na, Ji Yong Ahn, Kee Wook Jung, Jeong Hoon Lee, Do Hoon Kim, Ho June Song, Gin Hyug Lee, Jeong-Hwan Yook, Byung Sik Kim, Hwoon-Yong Jung
BACKGROUND: Endoscopic submucosal dissection (ESD) for early gastric cancer (EGC) meeting the expanded indication is considered investigational. We aimed to compare long-term outcomes of ESD and surgery for EGC in the expanded indication based on each criterion. METHODS: This study included 1823 consecutive EGC patients meeting expanded indication conditions and treated at a tertiary referral center: 916 and 907 patients underwent surgery or ESD, respectively. The expanded indication included four discrete criteria: (I) intramucosal differentiated tumor, without ulcers, size >2 cm; (II) intramucosal differentiated tumor, with ulcers, size ≤3 cm; (III) intramucosal undifferentiated tumor, without ulcers, size ≤2 cm; and (IV) submucosal invasion <500 μm (sm1), differentiated tumor, size ≤3 cm...
October 19, 2017: Gastric Cancer
Masahiro Iida, Fumie Ikeda, Jun Hata, Yoichiro Hirakawa, Tomoyuki Ohara, Naoko Mukai, Daigo Yoshida, Koji Yonemoto, Motohiro Esaki, Takanari Kitazono, Yutaka Kiyohara, Toshiharu Ninomiya
BACKGROUND: There have been very few reports of risk score models for the development of gastric cancer. The aim of this study was to develop and validate a risk assessment tool for discerning future gastric cancer risk in Japanese. METHODS: A total of 2444 subjects aged 40 years or over were followed up for 14 years from 1988 (derivation cohort), and 3204 subjects of the same age group were followed up for 5 years from 2002 (validation cohort). The weighting (risk score) of each risk factor for predicting future gastric cancer in the risk assessment tool was determined based on the coefficients of a Cox proportional hazards model in the derivation cohort...
October 17, 2017: Gastric Cancer
Waku Hatta, Takuji Gotoda, Tsuneo Oyama, Noboru Kawata, Akiko Takahashi, Yoshikazu Yoshifuku, Shu Hoteya, Masahiro Nakagawa, Masaaki Hirano, Mitsuru Esaki, Mitsuru Matsuda, Ken Ohnita, Kohei Yamanouchi, Motoyuki Yoshida, Osamu Dohi, Jun Takada, Keiko Tanaka, Shinya Yamada, Tsuyotoshi Tsuji, Hirotaka Ito, Yoshiaki Hayashi, Tomohiro Nakamura, Naoki Nakaya, Tooru Shimosegawa
BACKGROUND: We have established a risk-scoring system, termed the "eCura system," for the risk stratification of lymph node metastasis in patients who have received noncurative endoscopic submucosal dissection (ESD) for early gastric cancer (EGC). We aimed to clarify whether this system contributes to the selection of patients requiring radical surgery after ESD. METHODS: Between 2000 and 2011, 1,969 patients with noncurative ESD for EGC were included in this multicenter study...
October 5, 2017: Gastric Cancer
Kazumasa Fujitani, Yukinori Kurokawa, Atsushi Takeno, Shunji Endoh, Takeshi Ohmori, Junya Fujita, Makoto Yamasaki, Shuji Takiguchi, Masaki Mori, Yuichiro Doki
BACKGROUND: Surgical resection with S-1 adjuvant chemotherapy (AC) is the standard of care for stage II-III gastric cancer (GC). However, it is unclear if time to initiation and duration of S-1 AC impact on survival. METHODS: A multi-institutional GC database identified 498 patients who were treated with S-1 AC after D2 or more extended radical surgery for stage II-III gastric cancer. Patients were divided into four groups according to the interval between surgery and initiation of AC and the duration of AC as follows: group A (n = 226), who received AC earlier (≤6 weeks) and for longer (≥6 months) after surgery; group B (n = 160), who received AC later (>6 weeks) and for longer after surgery; group C (n = 46), who received AC earlier but for a shorter period (<6 months) after surgery; and group D (n = 66), who received AC later and for a shorter period after surgery...
September 30, 2017: Gastric Cancer
Haejin In, Ethan Ravetch, Marisa Langdon-Embry, Bryan Palis, Jaffer A Ajani, Wayne L Hofstetter, David P Kelsen, Takeshi Sano
PURPOSE: New stage grouping classifications for clinical (cStage) and post-neoadjuvant treatment (ypStage) stage for gastric adenocarcinoma have been proposed for the eighth edition of the AJCC manual. This article summarizes the analysis for these stages. METHODS: Gastric adenocarcinoma patients diagnosed in 2004-2009 were identified from the National Cancer Database (NCDB). The cStage cohort included both surgical and nonsurgical cases, and the ypStage cohort included only patients who had chemotherapy or radiation therapy before surgery...
September 25, 2017: Gastric Cancer
Yutaka Kimura, Masashi Fujii, Toshiki Masuishi, Kazuhiro Nishikawa, Chikara Kunisaki, Satoshi Matsusaka, Yoshihiko Segawa, Masato Nakamura, Kinro Sasaki, Narutoshi Nagao, Yukimasa Hatachi, Yasuhiko Yuasa, Shinya Asami, Masahiro Takeuchi, Hiroshi Furukawa, Toshifusa Nakajima
BACKGROUND: S-1 plus cisplatin is a standard regimen for advanced gastric cancer (AGC) in Asia. The ToGA trial established a fluoropyrimidine plus cisplatin and trastuzumab as a standard treatment for human epidermal growth factor receptor 2 (HER2)-positive AGC. In the HERBIS-1 trial, trastuzumab combined with S-1 plus cisplatin showed promising antitumor activity in patients with HER2-positive AGC. However, cisplatin has several important drawbacks, including vomiting and renal toxicity...
September 21, 2017: Gastric Cancer
Naoki Hiki, Michitaka Honda, Tsuyoshi Etoh, Kazuhiro Yoshida, Yasuhiro Kodera, Yoshihiro Kakeji, Hikaru Kumamaru, Hiroaki Miyata, Yuichi Yamashita, Masafumi Inomata, Hiroyuki Konno, Yasuyuki Seto, Seigo Kitano
BACKGROUND: Laparoscopic distal gastrectomy (LDG) is becoming the standard procedure for gastric cancer. However, supporting evidence thus far has been derived primarily from randomized control trials conducted by centers of excellence. In the present study we used the National Clinical Database (NCD) in Japan to prospectively accumulate data from diverse types of hospitals and examine whether LDG is a safe and valid standard procedure. METHODS: From the NCD, 169 institutions were selected to form a cohort that was considered to be representative of Japan...
September 8, 2017: Gastric Cancer
Yasuko Fujita, Mitsuo Kishimoto, Osamu Dohi, Kazuhiro Kamada, Atsushi Majima, Reiko Kimura-Tsuchiya, Nobuaki Yagi, Hideyuki Konishi, Yuji Naito, Yoshinori Harada, Hideo Tanaka, Eiichi Konishi, Tamotsu Sugai, Akio Yanagisawa
BACKGROUND: Endoscopic findings have now become nearly as detailed as histopathological findings. Thus, one-to-one correspondence and precise feedback of histopathological findings is very desirable but may be very difficult to accomplish. We describe a systematic process called the Kyoto One-to-One Correspondence Method (the KOTO Method) that allows detailed adjustments of endoscopic findings to match histopathological findings. METHODS AND RESULTS: By comparing endoscopic and stereoscopic images of the gastric mucosa, we could obtain one-to-one correspondence between endoscopic images and equivalent histology in 44 of 47 fields...
September 5, 2017: Gastric Cancer
Zongqiong Sun, Xiaofang Cheng, Yuxi Ge, Lin Shao, Yinghua Xuan, Gen Yan
BACKGROUND: This study used low-dose computed tomography (CT) perfusion imaging technology to evaluate the efficacy of neoadjuvant chemotherapy in patients with advanced gastric adenocarcinoma and to determine whether any of the perfusion parameters could predict tumor response to chemotherapy. METHODS: Forty patients with gastric adenocarcinoma (T3-4NxM0) received three cycles of neoadjuvant chemotherapy and low-dose spiral CT perfusion imaging prior to and after the first and third series of chemotherapy...
September 4, 2017: Gastric Cancer
Joonas H Kauppila, Cecilia Ringborg, Asif Johar, Jesper Lagergren, Pernilla Lagergren
BACKGROUND: The postoperative health-related quality of life (HRQOL) outcomes in patients with gastroesophageal junction (GEJ) adenocarcinoma after gastrectomy and esophagectomy are unclear. The aim was to evaluate HRQOL outcomes 6 months after extended total gastrectomy, subtotal esophagectomy, and combined esophagogastrectomy. METHODS: Patients who underwent surgery for GEJ adenocarcinoma of Siewert type 2 or 3 in 2001-2005 were identified from a nationwide Swedish prospective and population-based cohort...
August 29, 2017: Gastric Cancer
Yasutoshi Kuboki, Christoph A Schatz, Karl Koechert, Sabine Schubert, Janine Feng, Sabine Wittemer-Rump, Karl Ziegelbauer, Thomas Krahn, Akiko Kawano Nagatsuma, Atsushi Ochiai
BACKGROUND: Fibroblast growth factor receptor (FGFR2) has been proposed as a target in gastric cancer. However, appropriate methods to select patients for anti-FGFR2 therapies have not yet been established. METHODS: We used in situ techniques to investigate FGFR2 mRNA expression and gene amplification in a large cohort of 1036 Japanese gastric cancer patients. FGFR2 mRNA expression was determined by RNAscope. FGFR2 gene amplification was determined by dual-color in situ hybridization (DISH)...
August 29, 2017: Gastric Cancer
Sun Young Kim, Min Joo Yoon, Young Iee Park, Mi Jung Kim, Byung-Ho Nam, Sook Ryun Park
BACKGROUND: Some clinicopathological variables are known to influence the survival of patients with advanced gastric cancer. A comprehensive model based on these factors is needed for prediction of an individual's survival and appropriate patient counseling. METHODS: A nomogram for predicting 1-year survival in patients with advanced gastric cancer in the palliative chemotherapy setting was developed using clinicopathological data from 949 patients with unresectable or metastatic gastric cancer who had received first-line doublet cytotoxic chemotherapy from 2001 to 2006 at the National Cancer Center, Korea (Baseline Nomogram)...
August 21, 2017: Gastric Cancer
Haruna Furukawa, Yukinori Kurokawa, Shuji Takiguchi, Koji Tanaka, Yasuhiro Miyazaki, Tomoki Makino, Tsuyoshi Takahashi, Makoto Yamasaki, Kiyokazu Nakajima, Masaki Mori, Yuichiro Doki
BACKGROUND: Total or proximal gastrectomy is usually performed for early proximal gastric carcinoma, but the optimal type of gastrectomy is still unknown. We evaluated short-term outcomes and nutritional status after laparoscopic subtotal gastrectomy (LsTG) in comparison with laparoscopic total gastrectomy (LTG) and laparoscopic proximal gastrectomy (LPG). METHODS: We analyzed 113 patients who underwent LsTG (n = 38), LTG (n = 48), or LPG (n = 27) for cStage I gastric cancer located in the upper third of the stomach...
August 20, 2017: Gastric Cancer
Andrew J Martin, Emma Gibbs, Katrin Sjoquist, Nick Pavlakis, John Simes, Tim Price, Jenny Shannon, Sanjeev Gill, Vikram Jain, Geoffrey Liu, George Kannourakis, Yeul Hong Kim, Jin Won Kim, David Goldstein
BACKGROUND: The INTEGRATE phase II multinational randomized controlled trial demonstrated the activity of regorafenib on progression-free survival (PFS) in patients with refractory advanced gastric adenocarcinoma. We sought to evaluate whether these PFS gains had the potential to be offset by quality of life (QoL) impacts from treatment side effects and to thereby determine the appropriateness of continuing development to phase III. METHODS: QoL was assessed in INTEGRATE at baseline and at each 4 weeks thereafter, until discontinuation of study treatment, using the QLQ-C30, STO22, and EQ-5D questionnaires...
August 16, 2017: Gastric Cancer
Marco Catarci, Manuele Berlanda, Giovanni Battista Grassi, Francesco Masedu, Stefano Guadagni
BACKGROUND: Gastrectomy for gastric cancer is a significant cause of secondary exocrine pancreatic insufficiency. Pancreatic enzyme replacement therapy may influence nutritional status and quality of life after gastrectomy, but the pertinent clinical research to date remains controversial. A randomized controlled trial to test this hypothesis was carried out. METHODS: After gastrectomy, 43 patients with gastric cancer were randomly assigned to a normal diet (Normal-d; n = 21) or to a pancreatic enzyme supplementation diet (PES-d; n = 22) and were followed up during a 12-month period, assessing nutritional status and quality of life through body mass index (BMI), instant nutritional assessment (INA) class status, serum pre-albumin (SPA) values, and GastroiIntestinal Quality of Life Index (GIQLI)...
August 14, 2017: Gastric Cancer
Kazuto Harada, Xiaochuan Dong, Jeannelyn S Estrella, Arlene M Correa, Yan Xu, Wayne L Hofstetter, Kazuki Sudo, Hisashi Onodera, Koyu Suzuki, Akihiro Suzuki, Randy L Johnson, Zhenning Wang, Shumei Song, Jaffer A Ajani
BACKGROUND: Programmed death ligand 1 (PD-L1) is a key protein upregulated by tumor cells to suppress immune responses. Tumor-associated macrophages (TAMs) play a major role in this immunosuppression, but the relationship between PD-L1 expression and TAMs remains unclear in gastric adenocarcinoma (GAC). We simultaneously examined expression of PD-L1 and TAMs in GAC. METHODS: We performed immunohistochemical staining for PD-L1, CD68 (pan-macrophage), and CD163 (M2-like macrophage) in 217 GAC samples using a tissue microarray...
August 11, 2017: Gastric Cancer
Akitaka Makiyama, Kohei Arimizu, Gen Hirano, Chinatsu Makiyama, Yuzo Matsushita, Tsuyoshi Shirakawa, Hirofumi Ohmura, Masato Komoda, Keita Uchino, Kyoko Inadomi, Shuji Arita, Hiroshi Ariyama, Hitoshi Kusaba, Yudai Shinohara, Miyuki Kuwayama, Tatsuhiro Kajitani, Hisanobu Oda, Taito Esaki, Koichi Akashi, Eishi Baba
BACKGROUND: Patients with advanced gastric cancer (AGC) are often treated with irinotecan monotherapy as salvage-line therapy. However, the survival benefit of this therapy remains to be elucidated. METHODS: Medical records of AGC patients who were treated with irinotecan monotherapy as salvage-line treatment in six institutions from 2007 to 2014 were reviewed. RESULTS: A total of 146 patients had prior fluoropyrimidine and taxane therapies, and 75...
August 10, 2017: Gastric Cancer
Sara Jamel, Sheraz R Markar, George Malietzis, Amish Acharya, Thanos Athanasiou, George B Hanna
BACKGROUND: Peritoneal cytology has been used as a part of the cancer staging of gastric cancer patients. The primary aim of this systematic review was to evaluate the value of peritoneal cytology as part of the staging of gastric cancer and survival prediction. The second aim was to establish if positive cytology may be modified by neoadjuvant therapy, to improve prognosis. METHODS: An electronic literature search was performed using Embase, Medline, Web of Science, and Cochrane library databases up to January 2016...
August 4, 2017: Gastric Cancer
Yusuke Sasaki, Satoru Iwasa, Shunsuke Okazaki, Masahiro Goto, Yasushi Kojima, Atsushi Naganuma, Kengo Nagashima, Yushi Nagai, Hidekazu Hirano, Yoshitaka Honma, Atsuo Takashima, Ken Kato, Tetsuya Hamaguchi
BACKGROUND: A combination of S-1 and cisplatin is recognized as one of the standard first-line chemotherapy regimens for patients with advanced gastric cancer. However, demographic analyses of pivotal phase III studies have showed that only a minority of treated patients were aged 76 years or older. The purpose of this phase II study was to evaluate the safety and efficacy of combination therapy with S-1 and cisplatin in elderly patients with chemotherapy-naive advanced gastric cancer...
August 1, 2017: Gastric Cancer
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"